Condition: Cervical Cancer · Neoadjuvant Chemoimmunotherapy · Fertility Preservation · Sponsor: Tongji Hospital
This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, EFS and OS.
This description comes directly from the study's public registry record.
Kezhen Li · 086-027-8362 · tjkeke@126.com
Jing Chen · 086-027-8362 · chenjing3223@126.com
Always discuss trial participation with your own doctor first.
| Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University | Guangzhou, Guangdong, China | Recruiting |
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06289062